Trial Profile
A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 09 Mar 2021 Status changed from active, no longer recruiting to discontinued.
- 13 Sep 2017 Status changed from discontinued to active, no longer recruiting.
- 12 Sep 2017 Status changed from recruiting to discontinued.